OSR Health, A Message From the CEO
Rhea-AI Summary
OSR Health (NASDAQ:OSRH) CEO Peter Hwang outlined a proposed Shareholder Loyalty CVR Program designed to grant existing investors up to five additional shares per CVR, potentially increasing their position to six times the original if all four cumulative price and holding-period tiers are met ($2, $3, $4, $5 over 3, 6, 9, 12 months).
The letter highlights VXM01, licensed from Vaximm, with up to $815 million in potential milestones and an independent risk-adjusted NPV of about $94 million. OSR Health also holds a $15 million cash Put Option against BCM Europe AG, exercisable from October 29, 2026. Management notes Woori IO, a noninvasive glucose monitoring portfolio company, as an asset they believe the market has not fully considered. The CVR record date is set for August 14, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Shareholder Loyalty CVR Program offers up to 5 extra shares per CVR, potentially 6× original holdings
- VXM01 milestones contractually up to $815 million with ~$94 million risk-adjusted NPV
- $15 million Put Option against BCM Europe AG, exercisable from October 29, 2026
- CVR record date set for August 14, 2026, rewarding existing shareholders who continue holding
- Four cumulative CVR tiers with price triggers from $2 to $5 over 12 months
Negative
- CVR share rewards depend on meeting price triggers of $2, $3, $4, and $5
- Program could create share dilution by issuing up to 5 additional shares per CVR
- $15 million Put Option is not exercisable until October 29, 2026
- Exploration of earlier Put Option exercise has no assurance of any modification being agreed
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 02 | analyst flash report | Positive | +3.4% | External research reaffirmed a bullish rating and detailed the CVR loyalty program. |
| Jun 25 | loyalty program launch | Positive | -4.9% | Company formally introduced shareholder loyalty CVRs with potential five extra shares per CVR. |
| Jun 22 | corporate rebranding | Neutral | -5.3% | Name change to OSR Health and reiteration of VXM01 licensing milestones and Woori IO plans. |
| Jun 03 | strategic CEO letter | Positive | +3.4% | CEO outlined strategy, VXM01 licensing progress, Woori IO development, and Nasdaq compliance focus. |
| May 27 | VXM01 IP acquisition | Positive | -2.2% | Company agreed to acquire full VXM01 IP portfolio tied to existing BCME license economics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OSR Health news has produced mixed reactions, with several positive strategic updates met by both gains and selloffs.
Key Terms
contingent value rights financial
put option financial
continuous glucose monitoring medical
market capitalization financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.
To Every OSR Health Shareholder:
OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market. Before that recognition arrives, I want to speak to the shareholders who have been here all along.
You chose to believe in what we are building at a time when it was not easy to hold. You have stayed through volatility, through noise, and through a share price that has not yet reflected what we believe this company is worth. I see it. Our Board sees it. And we have designed the Shareholder Loyalty CVR Program specifically to recognize it.
Our proposed program is not a reverse split, and not a mechanical adjustment that leaves you with the same economic position dressed up differently, but a genuine reward - additional shares, at no cost, delivered automatically as we climb together toward price levels that reflect what we firmly believe to be our real fundamental value.
Hold through the three-month measurement date and reach
Tier | Holding Period | Price Trigger | Additional Shares | Your Position |
Tier 1 | 3 months | ≥ | + 0.5 shares / CVR | 1.5× original |
Tier 2 | 6 months | ≥ | + 1.0 shares / CVR | 2.5× original |
Tier 3 | 9 months | ≥ | + 1.5 shares / CVR | 4.0× original |
Tier 4 | 12 months | ≥ | + 2.0 shares / CVR | 6.0× original |
All tiers are cumulative. A holder who satisfies all four measurement dates will receive five additional shares per CVR - a total position of six times the original.
What the Market is Missing
Let me be direct about where we stand fundamentally, because I believe the current share price represents one of the most significant disconnects from underlying value I have seen in my career.
▸ VXM01 -
Vaximm's VXM01 has been licensed. The agreement is signed, the milestone stream of up to
But there is a second disconnect that is, if anything, even more striking.
As part of the licensing transaction, OSR Health holds a Put Option exercisable against BCM Europe AG - the right to put shares to BCME and receive
BCME's obligation is backed by a strategic investor - one whose prior relationship with our portfolio companies has been publicly disclosed - is ready to stand behind BCME's capacity to settle. The Put Option is exercisable from October 29, 2026. We are also exploring, in good faith, whether an earlier exercise at a mutually agreed price better reflecting current market conditions may serve both parties' interests - though no agreement has been reached and there is no assurance that any such modification will be agreed upon.
▸ Woori IO - A Market That Has Not Yet Looked
Woori IO is a newer addition to our portfolio which we believe the market has yet to price. Noninvasive continuous glucose monitoring is not a distant future - it is the next chapter of a market that has already proven to be enormous. The leading players listed in the US markets command valuations in the tens of billions. But consider even Korean comparable public companies with minimally invasive CGM technology that can carry a market capitalization of approximately
Woori IO is pursuing fully noninvasive technology in a world in which metabolic health monitoring is rapidly becoming part of everyday life, even for people without any specific medical diagnosis, and in which more than half a billion people live with diabetes or pre-diabetes. We believe the market has yet to look at what Woori IO represents. We have, and we are building accordingly.
What We Are Asking
We have decided on the CVR Record Date to be August 14, 2026. Own before then and hold. That is the entirety of what we are asking - the reward of up to six times your original position will be delivered in accordance with the program terms.
We built this program because we believe our shareholders deserve special recognition through a direct, proportional share in the upside of a company they already own, reserved exclusively for the shareholders who stay the course with us.
We look forward to delivering on every tier.
Sincerely,
Peter Hwang
Chief Executive Officer
OSR Health, Inc. (NASDAQ:OSRH)
About OSR Health, Inc.
OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.
Investor Contact
OSR Health, Inc.
Investor Relations
ir@osr-health.com
Forward Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Shareholder Loyalty CVR Program and its terms and timeline; the VXM01 licensing agreement and associated milestone payments; the Put Option exercisable against BCM Europe AG and any potential modification thereof; the Avance Life Sciences AG risk-adjusted NPV analysis; the commercial potential of Woori IO's noninvasive glucose monitoring technology; and the Company's views on the relationship between its current market capitalization and underlying fundamental value.
The CVR Program is subject to significant regulatory and corporate conditions that must be satisfied before implementation. The Company intends to seek confirmation from the SEC Staff through a no-action request that the CVR distribution may proceed in reliance on the Section 3(a)(9) exemption from Securities Act registration - and there is no assurance that such confirmation will be granted or granted on any particular timeline. If registration is required instead, the Company will file a Form S-1 or S-3 and the program will be delayed until such registration becomes effective. The program is also conditioned upon stockholder approval of an increase in authorized shares from 100,000,000 to 250,000,000. The CVR Record Date of August 14, 2026 has been established by the Board, but CVR distribution and share delivery will not occur until all regulatory and corporate conditions have been satisfied.
These and other forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, including: the outcome and timeline of the SEC no-action process or registration; receipt of required stockholder approvals; the Company's ability to maintain its Nasdaq listing through the August 31, 2026 compliance deadline; Vaximm AG's ability to achieve the milestones underlying the VXM01 licensing agreement; BCM Europe AG's ability to satisfy its Put Option obligations; and Woori IO's development and commercialization progress. Additional risk factors are described in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The Avance Life Sciences AG NPV analysis reflects assumptions that may differ from other methodologies and is not a guarantee of future payments or valuation. The Put Option terms referenced herein are contractual and should not be construed as a share price representation.
The Company undertakes no obligation to update any forward-looking statement except as required by law.
SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire